9 Result(s)

Article

Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications

Circulating immune cells play a pathogenic role in multiple sclerosis (MS). However, the role of specific lymphocyte subpopulations is not unveiled yet, especially in progressive stages. We aimed to investigat...

Antonio Luca Spiezia, Giulia Scalia, Maria Petracca… in Journal of Neurology (2024)

Article

ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis

ChatGPT is an open-source natural language processing software that replies to users’ queries. We conducted a cross-sectional study to assess people living with Multiple Sclerosis’ (PwMS) preferences, satisfac...

Elisabetta Maida, Marcello Moccia, Raffaele Palladino… in Journal of Neurology (2024)

Article

The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis

The wearing-off phenomenon is common in people with multiple sclerosis (MS) treated with ocrelizumab. We aim to evaluate the presence and severity of wearing-off to ocrelizumab in relation to demographic and M...

Isabel Monteiro, Valerio Nicolella, Mariano Fiorenza… in Journal of Neurology (2024)

Article

SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose

COVID-19 vaccines have been recommended to people with multiple sclerosis (pwMS) and, to ensure durable immunity, a third booster dose has been administered in several countries. Data about potential risks ass...

Massimiliano Di Filippo, Diana Ferraro, Paolo Ragonese… in Journal of Neurology (2024)

Article

Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study

We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes, neutrophils and immunoglobulins: (1) when compared with p...

Nicola Capasso, Raffaele Palladino, Vincenza Cerbone… in Journal of Neurology (2023)

Article

Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy

We aim to provide real-world evidence on the use of ocrelizumab for treating multiple sclerosis (MS), with specific regard to prescription pattern, adherence, persistence, healthcare resource utilization and r...

Marcello Moccia, Giuseppina Affinito, Giulia Berera… in Journal of Neurology (2022)

Article

Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study

Patients with multiple sclerosis (MS) often receive disease-modifying therapies (DMTs) that can expose them to reactivation of potential occult hepatitis B virus (HBV) infection (pOBI). We aimed to evaluate th...

Antonio Riccardo Buonomo, Giulio Viceconte, Massimiliano Calabrese… in Journal of Neurology (2022)

Article

Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study

Antonio Riccardo Buonomo, Giulio Viceconte, Massimiliano Calabrese… in Journal of Neurology (2022)

Article

Erratum to: Apathy in untreated, de novo patients with Parkinson’s disease: validation study of Apathy Evaluation Scale

Gabriella Santangelo, Paolo Barone, Sofia Cuoco, Simona Raimo… in Journal of Neurology (2014)